Based on non-pregnancy data, BP should be treated to <140/90 mmHg in women with
learn more a co-morbid condition, and further to <130/80 mmHg in women with pre-gestational diabetes mellitus . There is no clear best choice of agent . Antihypertensives used most commonly in pregnancy, as well as captoprial and enalapril are “usually acceptable” for breastfeeding  and , but caution may be exercised in preterm and low birth weight infants due to immature drug clearance and/or increased susceptibility to drug effects. Generally, antihypertensives are needed longer in women with preeclampsia (≈2 weeks) vs. gestational hypertension (≈1 week) . Non-steroidal anti-inflammatory drugs (NSAIDs), often self-administered analgesics, may exacerbate hypertension or cause acute kidney injury, and may best be avoided with resistant hypertension, high serum creatinine, or low platelet counts . Thromboprophylaxis use should be based on number of thromboembolic risk markers, especially preeclampsia associated with adverse perinatal outcome, advanced maternal age, obesity, prolonged antenatal bed rest, postpartum haemorrhage, and emergency Caesarean delivery ,  and . The duration of thromboprophylaxis may vary from until full mobilization to 4–6 weeks postpartum (also, see ‘Anaesthesia’). 1. Women with a history of severe preeclampsia (particularly those who presented
or delivered before 34 weeks’
gestation) should be screened for pre-existing hypertension and underlying renal disease (II-2B; Low/Weak). Gestational hypertension usually resolves by 6 weeks postpartum, check details CYTH4 while the hypertension of severe preeclampsia may take 3–6 months . Routine measurement of microalbuminuria after preeclampsia resolution is not recommended without a specific renal indication. Any abnormalities should prompt further investigation and appropriate specialist referral. Screening for other underlying causes of preeclampsia (e.g., renal disease) may better inform management of the woman’s health between (or after) pregnancies, or in subsequent pregnancies. Thrombophilia confers, at most, a weakly increased risk of preeclampsia (and other placentally mediated pregnancy complications), and thrombophilia screening following preeclampsia is not recommended . One exception may be preeclampsia with delivery at <34 weeks following which testing for antiphospholipid antibodies could be undertaken to diagnose the antiphospholipid syndrome . Any weight gain between pregnancies predicts preeclampsia and other pregnancy complications . Observational data suggest that in women who are morbidly obese, bariatric surgery lowers rates of subsequent HDP . Women with pre-existing hypertension should receive recommended cardiovascular risk factor screening and treatment .